PTO/SB/08b (09-06) Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

Sheet

APR 1 3 2007

THE THAPEN

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

	Complete if Known
Application Number	10/ 678,379
Filing Date	october 6 2003
First Named Inventor	Donald R. Van Deripe
Art Unit	
Examiner Name	Anadeus S. Lopez
Attomey Docket Number	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
/SD/		DONALD R. VANDERIPE, The		
		swelling of mitochondria from vitrogengus; a		
		possible cause of repentation damage; Medical		
		Hypothesis 62, ,294-296 (2004) ELsevier		
		/		
/SD/		YI PAN et al. Infarct Reduction		
		by washout of inhaled nitrosen with heliox		
<u>,</u>		or oxyged in a rat focal ischemic model.		
		Abstract: 59th Annual Meeting of the American		
;	,	Academy of Neurology - May 2007		
	1	Steven Douglas/		

Examiner Signature /Steven Douglas/ Date Considered 05/14/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

	Complete if Known
Application Number	10/ 678,379
Filing Date	october 6 2003
First Named Inventor	Donald R. Van Deripe
Art Unit	
Examiner Name	Anadeus S. Lopez
Attorney Docket Number	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
/SD/		DONALD R. VANDERIPE, The	
		swelling of mitochondria from nitrogengus; a	
••••••		possible cause of repertusion damage; Medical	
•••••		Hypothesis 62, p294-296 (2004) Elsevier	
		/'	.,
/SD/		YI PAN et. al. Infarct Reduction	
***************************************		by washout of inhaled nitrogen with heliox	
		or oxyged in a rat focal ischemic model.	
*******************************	****************	Abstract: 59th Annual Meeting of the American	
		Academy of Neurology - May 2007	
		05/00/2007	

Examiner Signature /Steven Douglas/ Date Considered 05/09/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{1.}Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.